| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780016 | Gynecologic Oncology | 2018 | 4 Pages |
Abstract
- Hormonal signaling is active in gynecologic tumors and involves tumor-stroma crosstalk.
- Progestins and aromatase inhibitors with mTOR inhibitors are clinically active in metastatic ER+/PR+ endometrial cancer.
- Systemic or local progestins enable fertility sparing in young women with early stage endometrial cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei,